Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Guided Therapeutics (GTHP) Shares Outstanding (Diluted Average) (2016 - 2025)

Guided Therapeutics (GTHP) has disclosed Shares Outstanding (Diluted Average) for 11 consecutive years, with $78.4 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) rose 36.76% to $78.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $78.4 million through Dec 2025, up 36.76% year-over-year, with the annual reading at $78.4 million for FY2025, 36.76% up from the prior year.
  • Shares Outstanding (Diluted Average) hit $78.4 million in Q4 2025 for Guided Therapeutics, down from $81.7 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $81.7 million in Q3 2025 to a low of $49297.0 in Q1 2023.
  • Historically, Shares Outstanding (Diluted Average) has averaged $42.3 million across 5 years, with a median of $50.4 million in 2023.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): plummeted 99.76% in 2023 and later surged 110961.53% in 2024.
  • Year by year, Shares Outstanding (Diluted Average) stood at $13.4 million in 2021, then surged by 142.99% to $32.5 million in 2022, then surged by 57.3% to $51.1 million in 2023, then increased by 12.14% to $57.3 million in 2024, then surged by 36.76% to $78.4 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for GTHP at $78.4 million in Q4 2025, $81.7 million in Q3 2025, and $73.6 million in Q2 2025.